Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 176 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Partial Seizure Clear all
Recruiting Phase 2 Interventional

An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures

NCT06908356
View directory record Official record
Conditions
Focal Onset Seizure, Primary Generalized Epilepsy
Interventions
30mg PRAX-628
Drug
Lead sponsor
Praxis Precision Medicines
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
8
States / cities
Phoenix, Arizona • Miami Lakes, Florida • Bethesda, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 22, 2026, 2:20 PM EDT
Completed Phase 3 Interventional Results available

An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam

NCT00761774
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
25
States / cities
Phoenix, Arizona • Fresno, California • Pasadena, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 22, 2026, 2:20 PM EDT
Withdrawn Phase 3 Interventional

Safety Study of Rufinamide Given as an add-on Therapy to Treat Patients With Seizures

NCT04558580
View directory record Official record
Conditions
Refractory Partial Seizures
Interventions
Rufinamide
Drug
Lead sponsor
University of South Alabama
Other
Eligibility
12 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 22, 2026, 2:20 PM EDT
Completed Phase 2 Interventional

E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

NCT00144690
View directory record Official record
Conditions
Epilepsy
Interventions
E2007 (perampanel), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 70 Years
Timeline
2005 – 2007
U.S. locations
5
States / cities
Little Rock, Arkansas • Tampa, Florida • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 22, 2026, 2:20 PM EDT
Completed No phase listed Observational

Phenotype and Etiology of Pallister-Hall Syndrome

NCT00001404
View directory record Official record
Conditions
Malformations, Multiple Abnormalies, Polydactyly
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
1,170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2016
U.S. locations
3
States / cities
Los Angeles, California • Bethesda, Maryland • Greenwood, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 22, 2026, 2:20 PM EDT
Completed Phase 3 Interventional Results available

Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures

NCT00419393
View directory record Official record
Conditions
Epilepsy
Interventions
Keppra XR (Levetiracetam XR)
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
12 Years to 75 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
16
States / cities
Dothan, Alabama • Northport, Alabama • Phoenix, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2014 · Synced Oct 22, 2026, 2:20 PM EDT
Completed Phase 4 Interventional Results available

Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures

NCT00955357
View directory record Official record
Conditions
Partial Epilepsies
Interventions
Lacosamide
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
17 Years and older
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
40
States / cities
Irvine, California • Rancho Mirage, California • Clearwater, Florida + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 22, 2026, 2:20 PM EDT
Completed Phase 2 Interventional Results available

Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures

NCT00871377
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, High Dose Fish Oil, Low Dose Fish Oil
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2014 · Synced Oct 22, 2026, 2:20 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs

NCT00866775
View directory record Official record
Conditions
Epilepsy With Simple or Complex Partial Onset Seizures
Interventions
Eslicarbazepine acetate
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
103
States / cities
Birmingham, Alabama • Mobile, Alabama • Northport, Alabama + 82 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 22, 2026, 2:20 PM EDT
Completed No phase listed Observational

Metabolic Abnormalities in Children With Epilepsy

NCT00001325
View directory record Official record
Conditions
Generalized Epilepsy, Infantile Spasms, Metabolic Disease, Partial Epilepsy, Seizures
Interventions
18 FDG
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 2:20 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures

NCT01397968
View directory record Official record
Conditions
Partial Epilepsy
Interventions
YKP3089, Placebo
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
16
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 22, 2026, 2:20 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures

NCT00524030
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
pregabalin 600 mg/day, pregabalin 150 mg/day
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
63
States / cities
Northport, Alabama • Phoenix, Arizona • Sun City, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 22, 2026, 2:20 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.

NCT00319501
View directory record Official record
Conditions
Seizures, Epilepsies, Partial, Epilepsy, Complex Partial, Epilepsy, Generalized, Epilepsy
Interventions
Placebo, Vanquix Auto-Injector (Diazepam Injection)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
86
States / cities
Northport, Alabama • Little Rock, Arkansas • Irvine, California + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 22, 2026, 2:20 PM EDT
Completed Phase 4 Interventional Results available

A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures

NCT03116828
View directory record Official record
Conditions
Epilepsy With Partial On-set Seizures
Interventions
Eslicarbazepine Acetate
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
53
States / cities
Mobile, Alabama • Phoenix, Arizona • Downey, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 22, 2026, 2:20 PM EDT
Completed Phase 3 Interventional Results available

Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older

NCT01243177
View directory record Official record
Conditions
Epilepsy, Monotherapy
Interventions
Lacosamide, Carbamazepine-Controlled Release
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
16 Years and older
Enrollment
888 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
15
States / cities
Alabaster, Alabama • Huntsville, Alabama • Phoenix, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 22, 2026, 2:20 PM EDT
Terminated Phase 3 Interventional

A Study of the Safety and Efficacy of Depakote Sprinkle Capsules in the Treatment of Partial Seizures in Children

NCT00067431
View directory record Official record
Conditions
Partial Seizure Disorder
Interventions
Divalproex Sodium (Depakote® Sprinkle Capsules)
Drug
Lead sponsor
Abbott
Industry
Eligibility
3 Years to 10 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
7
States / cities
Tampa, Florida • Cleveland, Ohio • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2006 · Synced Oct 22, 2026, 2:20 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

NCT03288129
View directory record Official record
Conditions
Partial Onset Seizures, Secondarily Generalized Seizures, Primary Generalized Tonic-Clonic Seizures
Interventions
Perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
4 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Oct 22, 2026, 2:20 PM EDT
Completed No phase listed Observational

Transcranial Magnetic Stimulation for the Treatment of Poorly Controlled Partial Epilepsy

NCT00001666
View directory record Official record
Conditions
Partial Epilepsy, Seizures
Interventions
Cadwell High-Speed Magnetoelectric Stimulator, Magpro High-Speed Magnetoelectric Stimulator
Device
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 2:20 PM EDT
Completed Phase 3 Interventional Results available

Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures

NCT00530855
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 70 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
77
States / cities
Alabaster, Alabama • Birmingham, Alabama • Northport, Alabama + 66 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 22, 2026, 2:20 PM EDT
Terminated Phase 4 Interventional

Effectiveness Study Comparing Treatment With Drug(s) or Adjunctive VNS Therapy for Pharmacoresistant Partial Seizures

NCT00215215
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
Vagus Nerve Stimulation Therapy
Device
Lead sponsor
Cyberonics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
23
States / cities
Phoenix, Arizona • Sun City, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2006 · Synced Oct 22, 2026, 2:20 PM EDT
Completed Phase 3 Interventional Results available

Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy

NCT01364597
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam (BRV)
Drug
Lead sponsor
UCB Pharma SA
Industry
Eligibility
28 Days to 17 Years
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
15
States / cities
Los Angeles, California • Gulf Breeze, Florida • Wellington, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 22, 2026, 2:20 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension

NCT01963208
View directory record Official record
Conditions
Drug Resistant Partial Onset Seizure
Interventions
ganaxolone, Placebo
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 22, 2026, 2:20 PM EDT
Recruiting Not applicable Interventional

Non-Invasive Low Intensity Focused Ultrasound Stimulation for Drug-Resistant Epilepsy

NCT07680842
View directory record Official record
Conditions
Drug-Resistant Epilepsy, Epilepsy, Epilepsy (Treatment Refractory), Epilepsy Comorbidities, Epilepsy, Drug Resistant, Epilepsy, Generalized, Epilepsy, Focal
Interventions
Target optimization using LIFU, Serial LIFU stimulation
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 22, 2026, 2:20 PM EDT
Completed Phase 3 Interventional

Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy

NCT00056576
View directory record Official record
Conditions
Epilepsy, Complex Partial
Interventions
Zonisamide
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
16 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
25
States / cities
Birmingham, Alabama • Huntsville, Alabama • Northport, Alabama + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2011 · Synced Oct 22, 2026, 2:20 PM EDT